Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 25, 2022Open Access

Vaccine effectiveness with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine against reported SARS-CoV-2 Delta and Omicron infection among adolescents, Norway, August 2021 to January 2022

View Full Paper
Ask AI
Bookmark
Share

Authors

LVLamprini VenetiNorwegian Institute of Public HealthJBJacob Dag BerildNorwegian Institute of Public HealthSWSara Viksmoen WatleNorwegian Institute of Public Health

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Veneti et al. (2022) studied this question.

synapsesocial.com/papers/6a158c0d9b87f33fc69fa72dhttps://doi.org/10.1101/2022.03.24.22272854
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Adolescent vaccination with BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine and effectiveness against COVID-19: national test-negative case-control study, England2021 · 16 citations
  2. 2Assessment of 135 794 Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2 Across the United States2020 · 246 citations
  3. 3Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 20212021 · 361 citations
  4. 4Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents2021 · 937 citations
  5. 5Estimation of Vaccine Efficacy in Non‐Randomly Mixing Populations1995 · 15 citations